LOADING
Comparing Procter & Gamble (PG) and Pfizer Inc (PFE) across the Consumer Staples and Health Care sectors. This side-by-side analysis covers price, valuation multiples, profitability, growth, dividends, and risk metrics to help investors evaluate these two stocks.
| Metric | PG | PFE |
|---|---|---|
| Price | $142.71 | $25.75 |
| Change Today | +0.33% | -0.81% |
| Market Cap | $331.2B | $148.0B |
| P/E Ratio | 21.0 | 19.8 |
| Forward P/E | 20.5 | 8.8 |
| PEG Ratio | 4.11 | 13.77 |
| EPS | $6.76 | $1.31 |
| Revenue Growth (YoY) | 7.4% | 5.4% |
| Profit Margin | 19.2% | 11.8% |
| Return on Equity | 31.1% | 8.3% |
| Dividend Yield | 2.94% | 6.65% |
| Beta | 0.40 | 0.30 |
| 52-Week High | $166.21 | $28.28 |
| 52-Week Low | $135.63 | $20.98 |
| Volume | 9.6M | 24.1M |
Procter & Gamble is the larger company by market capitalization. Pfizer Inc trades at a lower P/E ratio, suggesting it may offer better value relative to earnings. Pfizer Inc offers a higher dividend yield for income investors. Procter & Gamble has stronger profit margins. Both stocks should be evaluated in the context of your investment goals, risk tolerance, and portfolio diversification needs.